Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 1;2(2):e22654.
doi: 10.4161/onci.22654.

Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes

Adam W Mailloux  1 , Pearlie K Epling-Burnette
Affiliations

Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes

Adam W Mailloux et al. Oncoimmunology. .

Abstract

Myleodysplastic syndromes (MDS) are pre-malignant hematopoietic diseases that can progress to acute myeloid leukemia (AML) progression in conjunction with changes in immune function. In this model of leukemia evolution, the expansion of immunosuppressive regulatory T cells (Tregs) contributes to immune escape. Here, we discuss the importance of Treg-memory phenotype switching as a poor prognostic indicator in MDS.

Keywords: immune escape; immunoediting; leukemia; myelodysplastic syndrome; regulatory T cells.

PubMed Disclaimer

Figures

None
Figure 1. A schematic representation of regulatory T-cell memory phenotype switching in the context of MDS immunoediting as it relates to immunosuppression and response to immunosuppressive therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–48. doi: 10.1016/j.immuni.2004.07.017. - DOI - PubMed
    1. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 2006;107:628–36. doi: 10.1182/blood-2005-07-2737. - DOI - PMC - PubMed
    1. Epling-Burnette PK, List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol. 2009;16:70–6. doi: 10.1097/MOH.0b013e3283257ac7. - DOI - PubMed
    1. Calado RT. Immunologic aspects of hypoplastic myelodysplastic syndrome. Semin Oncol. 2011;38:667–72. doi: 10.1053/j.seminoncol.2011.04.006. - DOI - PMC - PubMed
    1. Sloand EM, Barrett AJ. Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success. Hematol Oncol Clin North Am. 2010;24:331–41. doi: 10.1016/j.hoc.2010.02.009. - DOI - PMC - PubMed

LinkOut - more resources